JP2012500786A - 組成物における改良又は組成物に関連した改良 - Google Patents

組成物における改良又は組成物に関連した改良 Download PDF

Info

Publication number
JP2012500786A
JP2012500786A JP2011523446A JP2011523446A JP2012500786A JP 2012500786 A JP2012500786 A JP 2012500786A JP 2011523446 A JP2011523446 A JP 2011523446A JP 2011523446 A JP2011523446 A JP 2011523446A JP 2012500786 A JP2012500786 A JP 2012500786A
Authority
JP
Japan
Prior art keywords
composition
flurbiprofen
pharmaceutically active
active compound
amylmetacresol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500786A5 (enExample
Inventor
アリステア キャンベル
Original Assignee
レキット ベンキサー ヘルスケア （ユーケイ） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0815405A external-priority patent/GB0815405D0/en
Priority claimed from GB0900288A external-priority patent/GB0900288D0/en
Application filed by レキット ベンキサー ヘルスケア （ユーケイ） リミテッド filed Critical レキット ベンキサー ヘルスケア （ユーケイ） リミテッド
Publication of JP2012500786A publication Critical patent/JP2012500786A/ja
Publication of JP2012500786A5 publication Critical patent/JP2012500786A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011523446A 2008-08-22 2009-08-18 組成物における改良又は組成物に関連した改良 Pending JP2012500786A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0815405A GB0815405D0 (en) 2008-08-22 2008-08-22 Novel compositions
GB0815405.6 2008-08-22
GB0900288.2 2009-01-09
GB0900288A GB0900288D0 (en) 2009-01-09 2009-01-09 Novel compositions
PCT/GB2009/002014 WO2010020772A2 (en) 2008-08-22 2009-08-18 Improvements in or relating to compositions

Publications (2)

Publication Number Publication Date
JP2012500786A true JP2012500786A (ja) 2012-01-12
JP2012500786A5 JP2012500786A5 (enExample) 2012-10-04

Family

ID=41343399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523446A Pending JP2012500786A (ja) 2008-08-22 2009-08-18 組成物における改良又は組成物に関連した改良

Country Status (14)

Country Link
US (2) US8569375B2 (enExample)
EP (1) EP2328549B1 (enExample)
JP (1) JP2012500786A (enExample)
KR (1) KR20110056500A (enExample)
CN (1) CN102131496B (enExample)
AU (1) AU2009284011B2 (enExample)
BR (1) BRPI0917191A2 (enExample)
CA (1) CA2733180A1 (enExample)
MX (1) MX344359B (enExample)
MY (1) MY155652A (enExample)
RU (1) RU2493829C2 (enExample)
TW (1) TW201010744A (enExample)
WO (1) WO2010020772A2 (enExample)
ZA (1) ZA201100960B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532121A (ja) * 2020-06-30 2023-07-26 グラクソスミスクライン・コンシューマー・ヘルスケア・ホールディングス・ユーエス・リミテッド・ライアビリティ・カンパニー ロゼンジ

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
CN102131496B (zh) * 2008-08-22 2013-10-23 雷克特本克斯尔保健(英国)有限公司 组合物的改进或与组合物有关的改进
US20120283668A1 (en) * 2011-05-04 2012-11-08 Pinchas Shalev Apparatus and method for using effervescent tablets for cosmetic care
US20130284637A1 (en) 2012-04-30 2013-10-31 Danisco Us Inc. Unit-dose format perhydrolase systems
KR20150100705A (ko) * 2013-04-18 2015-09-02 더 허쉬 컴퍼니 미분 점활제를 함유하는 식용물질
WO2016126217A1 (en) * 2015-02-03 2016-08-11 Pharmacti̇ve Ilaç Sanayi̇ Ve Ti̇caret A. Ş. Stable pharmaceutical combination containing benzydamine
CA3050738A1 (en) * 2017-02-01 2018-08-09 Johnson & Johnson Consumer Inc. A lozenge
AU2018300075B2 (en) * 2017-07-10 2024-02-29 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
WO2020013781A2 (en) 2018-03-27 2020-01-16 Pisak Mehmet Nevzat Synergistic effect of flurbiprofen and a gastro protective agent for the treatment of pain and inflammation
CN110812331A (zh) * 2018-08-10 2020-02-21 北京普德康利医药科技发展有限公司 一种氟比洛芬咽部滞留颗粒
RU2741388C1 (ru) * 2020-08-06 2021-01-25 Закрытое акционерное общество "АФОФАРМ" (ЗАО "АФОФАРМ") Лекарственный препарат в форме таблеток для профилактики и/или лечения простудных, острых респираторных и других инфекционно-воспалительных заболеваний горла и полости рта

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6216413A (ja) * 1985-07-12 1987-01-24 Teijin Ltd キチン類誘導体を用いた徐放性医薬品組成物
JPH09510703A (ja) * 1994-03-03 1997-10-28 ザ、プロクター、エンド、ギャンブル、カンパニー 経口ビヒクル組成物
JPH10203963A (ja) * 1996-10-29 1998-08-04 Montefarmaco Spa 殺菌性物質と粘膜付着性物質を含む口内投与用医薬品組成物
JP2001527567A (ja) * 1997-05-22 2001-12-25 ザ ブーツ カンパニー ピーエルシー フルルビプロフェン舐剤を製造する方法
JP2003002828A (ja) * 2001-04-17 2003-01-08 Tanabe Seiyaku Co Ltd 口腔粘膜等における炎症性疾患の予防・治療剤
JP2006182726A (ja) * 2004-12-28 2006-07-13 Lion Corp 粒状医薬組成物及びその製造方法
JP2007314529A (ja) * 2006-04-28 2007-12-06 Lion Corp 造粒粒子、錠剤、及び造粒粒子の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4988696A (en) * 1995-03-29 1996-10-16 Procter & Gamble Company, The Antitussive microcapsules
KR100598714B1 (ko) * 1995-12-21 2006-07-10 파마슈티스크 라보라토리움 페링 에이/에스 5-아미노살리실산을 함유하는 방출 제어형 경구용 약제학적조성물 및 장 질환을 치료하는 방법
WO2000035418A2 (en) * 1998-12-18 2000-06-22 Bayer Corporation Chewable drug delivery system
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
GB0113843D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
GB0515492D0 (en) * 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
EP2015761A4 (en) * 2006-03-29 2009-07-29 Naveh Pharma 1996 Ltd METHOD AND COMPOSITION FOR THE TREATMENT OF NUTRITIONAL IGNITION
US7754234B2 (en) * 2006-07-12 2010-07-13 Jones Thomas L Composition and method of treating a sore throat
CN102131496B (zh) * 2008-08-22 2013-10-23 雷克特本克斯尔保健(英国)有限公司 组合物的改进或与组合物有关的改进

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6216413A (ja) * 1985-07-12 1987-01-24 Teijin Ltd キチン類誘導体を用いた徐放性医薬品組成物
JPH09510703A (ja) * 1994-03-03 1997-10-28 ザ、プロクター、エンド、ギャンブル、カンパニー 経口ビヒクル組成物
JPH10203963A (ja) * 1996-10-29 1998-08-04 Montefarmaco Spa 殺菌性物質と粘膜付着性物質を含む口内投与用医薬品組成物
JP2001527567A (ja) * 1997-05-22 2001-12-25 ザ ブーツ カンパニー ピーエルシー フルルビプロフェン舐剤を製造する方法
JP2003002828A (ja) * 2001-04-17 2003-01-08 Tanabe Seiyaku Co Ltd 口腔粘膜等における炎症性疾患の予防・治療剤
JP2006182726A (ja) * 2004-12-28 2006-07-13 Lion Corp 粒状医薬組成物及びその製造方法
JP2007314529A (ja) * 2006-04-28 2007-12-06 Lion Corp 造粒粒子、錠剤、及び造粒粒子の製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013056441; 'コントロールリリースド製剤' 新・ドラッグデリバリーシステム , 2000, ｐ．７７-８５, 株式会社シーエムシー *
JPN6014031959; 廣川　薬科学大辞典〔第２版〕-机上版- , 19900625, ｐ．２７６左欄の「顆粒剤」, 株式会社廣川書店 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532121A (ja) * 2020-06-30 2023-07-26 グラクソスミスクライン・コンシューマー・ヘルスケア・ホールディングス・ユーエス・リミテッド・ライアビリティ・カンパニー ロゼンジ

Also Published As

Publication number Publication date
CA2733180A1 (en) 2010-02-25
BRPI0917191A2 (pt) 2015-11-10
ZA201100960B (en) 2012-04-25
AU2009284011B2 (en) 2013-12-12
MY155652A (en) 2015-11-13
CN102131496B (zh) 2013-10-23
US20110201685A1 (en) 2011-08-18
EP2328549B1 (en) 2017-11-15
EP2328549A2 (en) 2011-06-08
US20140039057A1 (en) 2014-02-06
KR20110056500A (ko) 2011-05-30
MX2011001950A (es) 2011-04-04
TW201010744A (en) 2010-03-16
RU2493829C2 (ru) 2013-09-27
AU2009284011A1 (en) 2010-02-25
RU2011110715A (ru) 2012-09-27
WO2010020772A3 (en) 2010-07-15
WO2010020772A2 (en) 2010-02-25
MX344359B (es) 2016-12-14
US8569375B2 (en) 2013-10-29
CN102131496A (zh) 2011-07-20

Similar Documents

Publication Publication Date Title
RU2493829C2 (ru) Улучшение композиций или того, что имеет отношение к композициям
US9579295B2 (en) Dosage form for insertion into the mouth
JP2012072166A (ja) 粘膜分配用組成物と方法
JP2000516222A (ja) 嚥下が容易な経口医薬組成物
RU2441648C2 (ru) Композиции частиц, включающие альгинат и/или альгиновую кислоту
CN110650732A (zh) 锭剂剂型
HK1158088A (en) Improvements in or relating to compositions
AU2006341307B2 (en) Particulate compositions comprising alginate and/or alginic acid
HK1123192A (en) Particulate compositions comprising alginate and/or alginic acid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140730